Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Z-902

Supelco

Zopiclone-D4 solution

100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C17H13ClN6O3D4
Número de CAS:
1435933-78-0
Peso molecular:
392.83
EC Number:
200-835-2
MDL number:
MFCD16295185
UNSPSC Code:
41116107
PubChem Substance ID:
329831620
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

100 μg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

O=C1C2=NC=CN=C2C(OC(N3C([2H])([2H])CN(C)CC3([2H])[2H])=O)N1C4=NC=C(Cl)C=C4

InChI

1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/i8D2,9D2

InChI key

GBBSUAFBMRNDJC-LZMSFWOYSA-N

Categorías relacionadas

General description

This internal standard is suitable for many LC/MS and GC/MS applications including forensic analysis, clinical toxicology, urine drug testing, or isotope dilution methods. Zopiclone is a non-benzodiazepine hypnotic sold under the trade names Imovane® and Zimovane and is prescribed for the treatment of insomnia.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Imovane is a registered trademark of Sanofi-Aventis
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Referencia del producto
Descripción
Precios

pictograms

FlameExclamation mark
GHS02,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

35.6 °F - closed cup

flash_point_c

2 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

O A H Reneerkens et al.
Psychopharmacology, 225(2), 303-312 (2012-08-03)
Sensory gating is an adaptive mechanism of the brain to prevent overstimulation. Patients suffering from clinical disorders such as Alzheimer's disease or schizophrenia exhibit a deficit in gating, which indicates not only an impairment in basic information processing that might
Osama Shaeer
The journal of sexual medicine, 10(2), 532-540 (2012-10-24)
Utility of phosphodiesterase inhibitors (PDEi's) for the treatment of erectile dysfunction (ED) has been the focus of experimental and clinical studies. However, public preferences, attitudes, and experiences with PDEi's are rarely addressed from a population/epidemiology viewpoint. The Global Online Sexuality
I A Korneev
Urologiia (Moscow, Russia : 1999), (2)(2), 106-108 (2013-06-26)
The arsenal of professionals providing assistance to men with erectile dysfunction includes a new, mouth dissolving dosage form of the vardenafil--levitra ODT. This form is effective, safe, and has a higher bioavailability as compared to vardenafil in the form of
Kristina Y Rust et al.
Therapeutic drug monitoring, 34(6), 729-735 (2012-11-07)
Phosphodiesterase type 5 inhibitors such as sildenafil, vardenafil, and tadalafil are a class of drugs used primarily in the treatment of erectile dysfunction. Sildenafil and tadalafil are also approved for the treatment of pulmonary hypertension. The aim of this study
Christoph Zenzmaier et al.
Endocrinology, 153(11), 5546-5555 (2012-09-06)
Phosphodiesterase type 5 (PDE5) inhibitors have been demonstrated to improve lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Because BPH is primarily driven by fibroblast-to-myofibroblast trans-differentiation, this study aimed to evaluate the potential of the PDE5 inhibitor vardenafil
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico